Prophylactic intravenous gentamicin with sedation-free cystoscopic injection of BoNT-A: No demonstrable adverse extravesical neuromuscular effects in a pilot safety study of 220 idiopathic overactive bladder patients

2021 ◽  
pp. 205141582110166
Author(s):  
Timothy P Napier-Hemy ◽  
Oladapo Feyisetan ◽  
Heather Stewart ◽  
Alaa Chamsin ◽  
Michael S Floyd ◽  
...  
Keyword(s):  
Single Dose ◽  
Side Effects ◽  
Overactive Bladder ◽  
Botulinum Toxin Type A ◽  
Concomitant Administration ◽  
Botulinum Toxin Type ◽  
Overactive Bladder Syndrome ◽  
Safety Study ◽  
Level Of Evidence ◽  
Intravesical Injection

Objectives: To determine whether administration of single dose prophylactic intravenous gentamicin prior to intravesical injection of botulinum toxin type A (BoNT-A) is associated with adverse extravesical neuromuscular effects in idiopathic overactive bladder syndrome. Patients and methods: A retrospective analysis of 220 consecutive idiopathic overactive bladder patients following sedation-free flexible cystoscopic injection of intravesical BoNT-A. All patients received a single dose of intravenous gentamicin (160 mg) followed by 100-200 IU of BoNT-A. They were followed up at intervals to determine whether they had experienced any adverse extravesical neuromuscular side effects. Results: None of our patients developed adverse extravesical neuromuscular side effects from intravesical botulinum injections with concomitant administration of intravenous gentamicin. Conclusion: Single dose intravenous gentamicin is safe to use as a prophylaxis for intravesical BoNT-A injections of 200 IU or below in idiopathic overactive bladder patients. Level of evidence: Not applicable.

scholarly journals Patient-Reported Side Effects of Intradetrusor Botulinum Toxin Type A for Idiopathic Overactive Bladder Syndrome

2011 ◽  
Vol 86 (1) ◽  
pp. 68-72 ◽  
Author(s):  
Ricarda M. Bauer ◽  
Christian Gratzke ◽  
Alexander Roosen ◽  
Yasmin Hocaoglu ◽  
Margit E. Mayer ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Overactive Bladder ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Overactive Bladder Syndrome ◽  
Patient Reported

scholarly journals The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy

2014 ◽  
Vol 47 (4) ◽  
pp. 528-532 ◽  
Author(s):  
José Abraão Carneiro Neto ◽  
Valéria Gusmão Bittencourt ◽  
Cassius de Oliveira ◽  
Rosana Andrade ◽  
Edgar Marcelino de Carvalho
Keyword(s):  
Botulinum Toxin ◽  
Overactive Bladder ◽  
Conventional Therapy ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type

scholarly journals Subcutaneous Botulinum Toxin Injections for the Treatment of Chronically Painful Post-Craniotomy Scars: A Case Report of Two Patients Treated Successfully for More Than Eight Years

2017 ◽  
pp. 39-42
Author(s):  
Dennis Dykstra
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Treatment Effectiveness ◽  
Trigger Point ◽  
Botulinum Toxin Type A ◽  
Tumor Resection ◽  
Botulinum Toxin Type ◽  
Pain Medications ◽  
Oral Pain ◽  
Pain Sensitization

Recently, the use of botulinum toxin type A (BoNT-A) has been reported to help with neuropathic pain reduction in numerous conditions, including painful chronic scar formation. The mechanism by which BoNT-A inhibits pain is unclear, but it appears to involve a reduction of peripheral pain sensitization, which indirectly reduces central pain sensitization. Two patients who underwent surgery for brain tumor resection developed chronic painful neuropathic postcraniotomy scars. Their scar pain was not relieved with oral pain medications or trigger point injections with steroids but was helped significantly with BoNT-A injections. In the first patient, over the past 8 years, we have gradually increased her scar BoNT-A dose to 150 units diluted 2:1 with normal saline (NS) and injected the dose at 20 sites around her scar. She now reports her scar pain is 80%-90% resolved with the effect lasting 10 to 11 weeks. She denies side effects at this dose. In the second patient, over 9 years, we gradually increased the BoNT-A dose to 175 units diluted 2:1 with NS at 30 sites around her scar and in the left occipital area. She now notes her scar pain is 70%-75% improved from baseline with the effect lasting 8 to 10 weeks followed by a gradual reduction in benefit. She reports no side effects with this dose. The results of this 2-patient case study suggests BoNT-A (specifically onabotulinumtoxinA) may be helpful for patients with chronic postcraniotomy scar pain. Further studies on the dose, injection sites and timing follow-up injections are needed to determine treatment effectiveness for this patient population. Key words: Scar pain, Botulinum toxin, chronic pain, subcutaneous, injections, post-craniotomy

Sign in / Sign up

Export Citation Format

Share Document